All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Is there still a role in MM for auto-SCT after induction with a quadruplet combination?
Featured:
Luciano CostaDuring the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Luciano J. Costa, University of Alabama at Birmingham, Birmingham, US. We asked, Is there still a role in multiple myeloma for autologous stem cell transplant (auto-SCT) after induction with a quadruplet combination?
Is there still a role in MM for auto-SCT after induction with a quadruplet combination?
In this video, Costa discusses the MASTER trial (NCT03224507), which involves the quadruplet drug combination of daratumumab, carfilzomib, lenalidomide, and dexamethasone (KRdD), followed by auto-SCT. The MASTER trial, updated during this congress, is critical to understand further how to implement minimal residual disease (MRD)-guided treatment decisions in the frontline setting and refine the use of auto-SCT.